國家衛生研究院 NHRI:Item 3990099045/5624
English  |  正體中文  |  简体中文  |  Items with full text/Total items : 12145/12927 (94%)
Visitors : 912006      Online Users : 1072
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
    •  Adv. Search
    Home ‧ Login ‧ Upload ‧ Help ‧ About ‧ Administer Goto mobile version


    Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/5624


    Title: Plasminogen activator inhibitor-1: the expression, biological function, and effects on tumorigenesis and tumor cell adhesion and migration
    Authors: Lee, CC;Huang, TS
    Contributors: National Institute of Cancer Research
    Abstract: Plasminogen activator inhibitor-1 (PAI-1) is a primary regulator of urokinase-type plasminogen activator (uPA). It inhibits uPA by forming a covalent complex, thus blocking uPA’s interaction with substrates. The half-life of active PAI-1 is < 1 h and it is easily transformed to a more stable inactive latent form. By binding with vitronectin, PAI-1 can be stabilized and remained its activity. PAI-1 expression is regulated by many intrinsic factors (e.g. cytokines, growth factors, hormones, and lipids) and extrinsic factors (e.g. physical injury and DNA-damaging agents). PAI-1 is an essential regulator in physiological thrombotic/fibrinolytic process in vessel. It is also in the extracellular matrix (ECM) where it controls local proteolysis via inhibiting uPA. PAI-1 can regulate cell adhesion via either inhibition of uPA or interference with the binding between cellular integrins or uPA receptor (uPAR) and vitronectin. In addition, PAI-1 can regulate cell migration by inducing clearance receptor-mediated cycled attachment-detachment-reattachment of integrins. PAI-1 may have a role in regulating tumor invasion, angiogenesis and metastasis. Elevated levels of both uPA and PAI-1 are associated with a poor prognosis in many cancers. However, most in vivo experiments revealed: (1) High level (pharmacological level) of PAI-1 prevented angiogenesis and tumorigenesis; (2) Low level (physiological level) of PAI-1 conversely facilitated tumor growth and angiogenesis, and (3) While in PAI-1-deficient host, tumor growth and angiogenesis could not progress. The conclusions of PAI-1 in cancer development are still controversial. Because PAI-1 may play a role in tumor cell migration and invasion through anti-proteinase activity and interference with cell attachment to ECM, some strategies can be considered to apply PAI-1 derivatives to cancer therapy.
    Date: 2005
    Relation: Journal of Cancer Molecules. 2005;1(1):25-36.
    Link to: http://mupnet.com/JOCM%201%281%29%2025.htm
    Appears in Collections:[Tze-Sing Huang] Periodical Articles

    Files in This Item:

    File Description SizeFormat
    NCA2011042104.pdf1790KbAdobe PDF697View/Open


    All items in NHRI are protected by copyright, with all rights reserved.

    Related Items in TAIR

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback